NKCC

Choose Selective NKCC Inhibitors

NKCC Products

  • All (5)
  • NKCC Inhibitors (5)
  • New NKCC Products
Catalog No. Product Name Information Product Use Citations Product Validations
E2358New Azosemide Azosemide is a potent Na+–K+–2Cl cotransporter NKCC1 inhibitor with IC50s of 0.246 µM for hNKCC1A and 0.197 µM for NKCC1B, respectively.
S1287 Bumetanide Bumetanide (Bumex) is a loop diuretic of the sulfamyl category to treat heart failure. Bumetanide is a selective Na+-K+-Cl- cotransporter 1 (NKCC1) inhibitor, weakly inhibits NKCC2, with IC50s of 0.68 and 4.0 μM for hNKCC1A and hNKCC2A, respectively.
Cell Mol Gastroenterol Hepatol, 2019, 10.1016/j
S1603 Furosemide (NSC 269420) Furosemide (NSC 269420) is a potent NKCC2 (Na-K-2Cl symporter) inhibitor, used in the treatment of congestive heart failure and edema.
Environ Toxicol Chem, 2021, 10.1002/etc.5018
Sci Rep, 2018, 8(1):9302
Biomed Pharmacother, 2018, 101:145-154
S5194 Furosemide sodium Furosemide (Frusemide) sodium is a potent and orally active inhibitor of Na-K-Cl cotransporter (NKCC). Furosemide sodium is a subtype-selective antagonist of gamma-aminobutyric acid type A (GABAA) receptor.
S8615 Sodium dichloroacetate (DCA) Sodium dichloroacetate (DCA, Dichloroacetic acid, bichloroacetic acid, BCA), a specific inhibitor of pyruvate dehydrogenase kinase (PDK) with IC50 values of 183 and 80 μM for PDK2 and PDK4 respectively, has been shown to derepress Na+-K+-2Cl- cotransporter and a mitochondrial potassium-ion channel axis. Sodium dichloroacetate increases reactive oxygen species (ROS) generation, triggers apoptosis in cancer cells, and inhibits tumor growth.
Nat Commun, 2022, 13(1):1417
Mol Oncol, 2022, 16(1):219-249
J Exp Clin Cancer Res, 2021, 40(1):87
E2358New Azosemide Azosemide is a potent Na+–K+–2Cl cotransporter NKCC1 inhibitor with IC50s of 0.246 µM for hNKCC1A and 0.197 µM for NKCC1B, respectively.
S1287 Bumetanide Bumetanide (Bumex) is a loop diuretic of the sulfamyl category to treat heart failure. Bumetanide is a selective Na+-K+-Cl- cotransporter 1 (NKCC1) inhibitor, weakly inhibits NKCC2, with IC50s of 0.68 and 4.0 μM for hNKCC1A and hNKCC2A, respectively.
Cell Mol Gastroenterol Hepatol, 2019, 10.1016/j
S1603 Furosemide (NSC 269420) Furosemide (NSC 269420) is a potent NKCC2 (Na-K-2Cl symporter) inhibitor, used in the treatment of congestive heart failure and edema.
Environ Toxicol Chem, 2021, 10.1002/etc.5018
Sci Rep, 2018, 8(1):9302
Biomed Pharmacother, 2018, 101:145-154
S5194 Furosemide sodium Furosemide (Frusemide) sodium is a potent and orally active inhibitor of Na-K-Cl cotransporter (NKCC). Furosemide sodium is a subtype-selective antagonist of gamma-aminobutyric acid type A (GABAA) receptor.
S8615 Sodium dichloroacetate (DCA) Sodium dichloroacetate (DCA, Dichloroacetic acid, bichloroacetic acid, BCA), a specific inhibitor of pyruvate dehydrogenase kinase (PDK) with IC50 values of 183 and 80 μM for PDK2 and PDK4 respectively, has been shown to derepress Na+-K+-2Cl- cotransporter and a mitochondrial potassium-ion channel axis. Sodium dichloroacetate increases reactive oxygen species (ROS) generation, triggers apoptosis in cancer cells, and inhibits tumor growth.
Nat Commun, 2022, 13(1):1417
Mol Oncol, 2022, 16(1):219-249
J Exp Clin Cancer Res, 2021, 40(1):87
E2358New Azosemide Azosemide is a potent Na+–K+–2Cl cotransporter NKCC1 inhibitor with IC50s of 0.246 µM for hNKCC1A and 0.197 µM for NKCC1B, respectively.
Tags: NKCC inhibitor|NKCC agonist|NKCC activator|NKCC inducer|NKCC antagonist|NKCC signaling pathway|NKCC assay kit